The human iPSC-cardiomyocyte arrhythmic risk (hCAR) assessment model to improve drug cardiac safety evaluation

被引：0
|
作者：
Guo, Liang [1 ]
Coyle, Luke [1 ]
Abrams, Rory [1 ]
Heidelberger, Cheryl [1 ]
Singer, Thomas [1 ]
Weiser, Thomas [1 ]
Chiao, Eric [1 ]
Kemper, Ray [1 ]
Kolaja, Kyle [1 ]
机构：
[1] Hoffmann La Roche Inc, Early & Invest Safety Nonclin Safety, Nutley, NJ 07110 USA
来源：
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS | 2013年 / 68卷 / 01期
关键词：
D O I：
10.1016/j.vascn.2013.01.092
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
085
引用
收藏
页码：E24 / E24
页数：1
相关论文
共 50 条
  • [1] Refining the Human iPSC-Cardiomyocyte Arrhythmic Risk Assessment Model
    Guo, Liang
    Coyle, Luke
    Abrams, Rory M. C.
    Kemper, Raymond
    Chiao, Eric T.
    Kolaja, Kyle L.
    [J]. TOXICOLOGICAL SCIENCES, 2013, 136 (02) : 581 - 594
  • [2] Assessment of drug-induced arrhythmic risk using limit cycle and autocorrelation analysis of human iPSC-cardiomyocyte contractility
    Kirby, R. Jason
    Qi, Feng
    Phatak, Sharangdhar
    Smith, Layton H.
    Malany, Siobhan
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2016, 305 : 250 - 258
  • [3] Development of a Human iPSC Cardiomyocyte-Based Scoring System for Cardiac Hazard Identification in Early Drug Safety De-risking
    Kopljar, Ivan
    Lu, Hua Rong
    Van Ammel, Karel
    Otava, Martin
    Tekle, Fetene
    Teisman, Ard
    Gallacher, David J.
    [J]. STEM CELL REPORTS, 2018, 11 (06): : 1365 - 1377
  • [4] Human Atrial Cardiac Microtissues for Chamber-Specific Arrhythmic Risk Assessment
    Soepriatna, Arvin H.
    Kim, Tae Yun
    Daley, Mark C.
    Song, Elena
    Choi, Bum-Rak
    Coulombe, Kareen L. K.
    [J]. CELLULAR AND MOLECULAR BIOENGINEERING, 2021, 14 (05) : 441 - 457
  • [5] Human Atrial Cardiac Microtissues for Chamber-Specific Arrhythmic Risk Assessment
    Arvin H. Soepriatna
    Tae Yun Kim
    Mark C. Daley
    Elena Song
    Bum-Rak Choi
    Kareen L. K. Coulombe
    [J]. Cellular and Molecular Bioengineering, 2021, 14 : 441 - 457
  • [6] Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment
    Yang, Xi
    Ribeiro, Alexandre J. S.
    Pang, Li
    Strauss, David G.
    [J]. TOXICOLOGICAL SCIENCES, 2022, 190 (02) : 117 - 126
  • [7] Novel 3D Primary Human Cardiomyocyte Culture System for Evaluation of Candidate Drug Related Cardiac Safety Profile
    Sharma, C. R.
    Sharma, M. R.
    Narayanan, P.
    Mallen, S.
    Bergersen, K.
    Amezcua, N.
    Staton, D.
    Navel, M.
    Rodriguez, R.
    Sharma, S.
    Amiri, M.
    Sharma, S.
    Jani, J.
    Wong, H.
    Kohana, J.
    Sharma, J.
    Collins, J.
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [8] Modelling and Simulation for Preclinical Cardiac Safety Assessment of Drugs with Human iPSC-Derived Cardiomyocytes
    Kügler P.
    [J]. Jahresbericht der Deutschen Mathematiker-Vereinigung, 2020, 122 (4) : 209 - 257
  • [9] Human Ipsc Derived Cardiac Tissue Matured by Spontaneous Traveling Waves for Improved Drug Assessment
    Li, Junjun
    Hua, Ying
    Qu, Xiang
    Sougawa, Nagako
    Sawa, Yoshiki
    Miyagawa, Shigeru
    Liu, Li
    Kawamura, Takuji
    [J]. CIRCULATION, 2021, 144
  • [10] An evaluation of risk assessment as a tool to improve patient safety and prioritise the resources
    Eidesen, K.
    Aven, T.
    [J]. RISK, RELIABILITY AND SOCIETAL SAFETY, VOLS 1-3: VOL 1: SPECIALISATION TOPICS; VOL 2: THEMATIC TOPICS; VOL 3: APPLICATIONS TOPICS, 2007, : 171 - 177
12345